Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( (DE:2TZ) ) just unveiled an update.
The board of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited convened its fourth board meeting for FY2025, passing key resolutions including an equity custody agreement with Tianjin Medicine Asset Management Co., Ltd. and Tianjin Pharmaceutical Group Jin Yi Tang Chain Co., Ltd., and a lease agreement with Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. Additionally, the board approved the appointment of Ms. Zhao Liyang as the company’s securities affairs representative. These decisions are part of the company’s strategic operations and governance, potentially impacting its market positioning and stakeholder relationships.
More about Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, is a company incorporated in the People’s Republic of China. It operates in the pharmaceutical industry, focusing on the management and development of pharmaceutical assets and products.
Learn more about 2TZ stock on TipRanks’ Stock Analysis page.